Navigation Links
UMass Boston's Venture Development Center Announces New Bio-Science Partner

Pressure BioSciences Inc. to Join University's R&D Facility

Boston, MA (Vocus) January 21, 2010 -- The University of Massachusetts Boston today announced that South Easton-based Pressure BioSciences Inc., (PBI) a developer of bench-top sample preparation instruments, has moved its research and development operations to the university's Venture Development Center. PBI develops and markets pressure cycling technology that enables safe, rapid, and reproducible extraction of proteins, DNA, RNA, and small molecules from biological samples for biochemical analysis.

This brings the 18,000-square-foot business incubator to 75 percent occupancy since opening in May 2009.

The addition of PBI is expected to greatly benefit the Center for Personalized Cancer Therapy, a joint UMass Boston venture with the Dana-Farber/Harvard Cancer Center to be launched within the VDC. The purpose of the CPCT is to conduct basic and translational research to develop low-cost diagnostic tests focusing on cancers that vary at the molecular level but remain indistinguishable in conventional clinical analyses.

“Our scientists connected with the Center for Personalized Cancer Therapy are excited about collaborating with PBI," said William Brah, executive director of the VDC. “The goals of CPCT are ideally complemented by the cutting-edge, PCT-based sample preparation technology developed by PBI, which can permit tumor biomarkers in ordinary clinical preparations to be more rapidly and effectively analyzed.”

UMass Boston has purchased PBI's Barocycler instrument, which offers shorter processing time, higher throughput, and reduced operating costs, all without sacrificing quality. The instrument will be available to UMass Boston scientists and students to enhance their research and training, and will also provide CPCT with an important tool for its translational research.

PBI, a publicly traded company (PBIO), began commercializing pressure cycling technology in 2005. It recently raised approximately $1.2 million to support on-going efforts to increase sales and applications for PCT. PBI currently has about 90 instrument installations worldwide.

In addition to Pressure BioSciences Inc., the VDC is home to:

  • DPixel, a management consulting company specialized in seed and early stage investments.
  • Anthurium Solutions, Inc., a software company building a platform for matching continuous digital work with virtual workers globally.
  • Symmetric Computing, a startup company commercializing advanced supercomputing technology.
  •, a technology-powered provider of retirement planning and investment management services.
  • GeoMed Analytical, a full service analytical testing and development laboratory.
  • Developmental Sciences Research Center/HORIZON, a translational research center focused on the study of community health.
  • Collaborative Institute for Oceans, Climate, and Security, a center focused on the security of living environments and global coastal communities.

About the Venture Development Center
The Venture Development Center is a research and development center and business incubator for entrepreneurs from within and outside UMass Boston. The center is designed to accelerate time to investment and market, while keeping costs to a minimum. The VDC offers short-term, ready-to-use offices and laboratories with managed services that meet the needs of startups. The VDC offers the ability to foster collaboration with the intellectual resources of UMass Boston's faculty, staff, and students. To learn more about the VDC, visit

About the University of Massachusetts Boston
With a growing reputation for innovative research addressing complex issues, the University of Massachusetts Boston, metropolitan Boston's only public university, offers its diverse student population both an intimate learning environment and the rich experience of a great American city. UMass Boston's seven colleges and graduate schools serve more than 14,000 students while engaging local, national, and international constituents through academic programs, research centers, and public service activities. To learn more about UMass Boston, visit

DeWayne Lehman, 617 287-5302
William Brah, 617 287-7723

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. UMass Boston Opens Venture Development Center to Expand R&D Activity
2. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
3. Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution
4. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
5. Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada
6. Bio-Organic Catalyst, Inc. Forms Joint Venture With SIF ICAP Mexico S.A. de C.V. as Exclusive Distribution Hub for Central America, Mexico and Caribbean.
7. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
8. Kansas Bioscience Authority Commits $50 Million to Increase Venture Capital, Accelerate Bioscience Business Growth
9. Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards
10. Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards
11. RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences
Post Your Comments:
Related Image:
UMass Boston's Venture Development Center Announces New Bio-Science Partner
(Date:11/30/2015)... includes an MPP licen c ... , s Solid Drug Nanoparticle (SDN) Technology ; Aims ... through cost cuts of priority ... anywhere in the world will have the right to make, use and distribute lower ... licensees based anywhere in the world will have the right to make, use and ...
(Date:11/30/2015)... Md. , Nov. 30, 2015 ... development company committed to the fostering and monetization ... the current and prospective initiatives designed to create ... Chief Executive Officer of Spherix. "Based on published ... future licensees exceeds $50 billion and Spherix will ...
(Date:11/30/2015)... 2015 TapImmune, Inc. (TPIV), ... innovative peptide and gene-based immunotherapeutics and vaccines for the ... will be presenting at the 8 th Annual ... 2.30 PM PT. Dr. John N. Bonfiglio ... giving the presentation and will join TapImmune management in ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December ... (ECNR) in Vienna, Austria to ... wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), ... NovaVision Therapy Suite at the 3rd European Congress of ...
Breaking Biology Technology:
(Date:11/19/2015)... Nov. 19, 2015  Although some 350 companies are ... by a few companies, according to Kalorama Information. These include ... of the market share of the 6.1 billion-dollar molecular ... World Market for Molecular Diagnostic s .    ... is still controlled by one company and only a ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
Breaking Biology News(10 mins):